These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

800 related items for PubMed ID: 17658994

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
    Ram M, Shoenfeld Y.
    Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
    [Abstract] [Full Text] [Related]

  • 5. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
    Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN.
    Adv Immunol; 2006 Sep; 90():215-41. PubMed ID: 16730265
    [Abstract] [Full Text] [Related]

  • 6. Immunopathogenesis of vitiligo.
    Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, Mendoza-Pinto C, Jiménez-Hernández M, Munguía-Realpozo P, Ruiz-Argüelles A.
    Autoimmun Rev; 2011 Oct; 10(12):762-5. PubMed ID: 21334464
    [Abstract] [Full Text] [Related]

  • 7. Physiopathology and genetics of vitiligo.
    Passeron T, Ortonne JP.
    J Autoimmun; 2005 Oct; 25 Suppl():63-8. PubMed ID: 16298511
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vitiligo and malignant melanoma.
    Fodor J, Bodrogi I.
    Neoplasma; 1975 Oct; 22(4):445-8. PubMed ID: 1196428
    [Abstract] [Full Text] [Related]

  • 12. Polyglandular autoimmune diseases in a dermatological clinical setting: vitiligo-associated autoimmune diseases.
    Amerio P, Di Rollo D, Carbone A, Auriemma M, Marra ME, De Remigis P, Feliciani C, Tracanna M, Tulli A.
    Eur J Dermatol; 2010 Oct; 20(3):354-8. PubMed ID: 20395193
    [Abstract] [Full Text] [Related]

  • 13. Immunological basis of melanoma-associated vitiligo-like depigmentation.
    González R, Torres-López E.
    Actas Dermosifiliogr; 2014 Mar; 105(2):122-7. PubMed ID: 23146137
    [Abstract] [Full Text] [Related]

  • 14. Autoimmune vitiligo: detection of antibodies to melanin-producing cells.
    Hertz KC, Gazze LA, Kirkpatrick CH, Katz SI.
    N Engl J Med; 1977 Sep 22; 297(12):634-7. PubMed ID: 331108
    [Abstract] [Full Text] [Related]

  • 15. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
    Garbelli S, Mantovani S, Palermo B, Giachino C.
    Pigment Cell Res; 2005 Aug 22; 18(4):234-42. PubMed ID: 16029417
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes.
    Shajil EM, Chatterjee S, Agrawal D, Bagchi T, Begum R.
    Indian J Exp Biol; 2006 Jul 22; 44(7):526-39. PubMed ID: 16872041
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
    Palermo B, Garbelli S, Mantovani S, Scoccia E, Da Prada GA, Bernabei P, Avanzini MA, Brazzelli V, Borroni G, Giachino C.
    Eur J Immunol; 2005 Nov 22; 35(11):3153-62. PubMed ID: 16224813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.